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Abstract
Background: A doxorubicin (DOX)-based chemotherapy protocol, CHOP, is the most effective treatment for canine
high-grade B-cell lymphoma; however, the cost and time requirements associated with this protocol are not
feasible for many pet owners. An alternative treatment option is the use of DOX, the most effective drug, in
combination with prednisone. Prior studies with single-agent DOX included dogs with T-cell lymphoma, a known
negative prognostic factor, which may have resulted in shorter reported survival times than if dogs with B-cell
lymphoma were analyzed separately. The purpose of this study was to evaluate the outcome of dogs with high-
grade B-cell lymphoma when treated with DOX and prednisone with or without L-asparaginase (L-ASP).
Identification of prognostic factors was of secondary interest.
Results: Thirty-three dogs were included in the study; 31 dogs were evaluable for response with an overall
response rate of 84%. The median progression free survival (PFS) and overall survival (OS) were 147 days and
182 days, respectively. The one-year survival fraction was 23%. No variable other than protocol completion was
found to be significant for either PFS or OS including historical prognostic factors such as substage,
thrombocytopenia, and body weight.
Conclusions: Dogs with high-grade B-cell lymphoma treated with DOX and prednisone with or without L-ASP
have similar response rates, PFS, and OS to prior studies that did not differentiate between lymphoma
immunophenotype. This protocol is not a replacement for CHOP; however, it is an alternative if time and cost are
factors, while providing therapeutic benefit greater than prednisone alone.
Keywords: Adriamycin, Cancer, Canine, Chemotherapy, Immunophenotype
Background
A doxorubicin (DOX)-based chemotherapy protocol in-
cluding cyclophosphamide, vincristine, and prednisone
(CHOP), with or without L-asparaginase (L-ASP), is the
most effective treatment for canine high-grade lymphoma.
CHOP has repeatedly shown remission rates greater than
85%, with response durations of 6 to 10 months and sur-
vival times of 8 to 12 months [1–5]. However, several stud-
ies have described distinct treatment outcomes between
high-grade B- and T-cell lymphoma demonstrating
immunophenotype as an important prognostic factor [6–
8]. When treated with a CHOP protocol, dogs with
high-grade T-cell lymphoma have significantly shorter re-
mission and survival times compared to those reported for
dogs with high-grade B-cell lymphoma [9]. Multi-agent
protocols report similar response rates for dogs with B- and
T-cell lymphoma [10, 11]. However, response rates to a sin-
gle dose of DOX for dogs with T-cell lymphoma is 50%
compared to a 100% response rate for dogs B-cell lymph-
oma, suggesting that DOX may be a less efficacious drug
for the treatment of T-cell lymphoma in dogs [12]. When
deciding on a course of therapy for a dog with lymphoma,
many owners consider prognosis as well as cost and time
commitment of treatment. The financial burden and time
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requirement to pursue a CHOP protocol is not feasible for
many pet owners, necessitating alternative options when
CHOP is declined.
DOX is the most effective single-agent drug for the
treatment of canine high-grade lymphoma and DOX
combined with prednisone may be offered as an alterna-
tive option to CHOP [13, 14]. This may be a more prac-
tical treatment for owners seeking to extend quality of
life beyond that obtained with prednisone alone, but
who are interested in a less intense protocol in terms of
frequency and total number of treatments as well as cost
[9]. When administered as a single-agent protocol, DOX
is typically administered once every 3 weeks for 5 to 6
treatments whereas a CHOP protocol may consist of 12
to 17 chemotherapy treatments administered over 15 to
26 weeks. Outcome of dogs with lymphoma treated with
a single-agent DOX protocol is inferior to CHOP, with
shorter remission durations (4 to 6 months) and de-
creased survival times (5 to 9 months) despite relatively
similar response rates (74 to 88%) [15–19]. However,
previous studies evaluating DOX administered every
3 weeks for 5 to 6 treatments have not examined the as-
sociation of patient outcome and immunophenotype.
This raised the question as to whether prior studies that
included dogs with T-cell lymphoma may underestimate
survival times for dogs with B-cell lymphoma treated
with single-agent DOX. The objective of this retrospect-
ive study was to investigate the outcome of dogs with
high-grade B-cell lymphoma treated with DOX and
prednisone with or without L-ASP. We hypothesized
that these dogs would have an improved overall re-
sponse rate, progression-free survival (PFS), and overall
survival (OS) as compared to previous studies that in-
cluded dogs with B- and T-cell lymphoma. Identification
of factors associated with improved patient outcome was
a secondary objective.
Results
Patient characteristics
Thirty-three dogs with high-grade B-cell lymphoma
treated with at least one dose of DOX between January
2008 and December 2015 were included in the study. In-
formation regarding signalment, weight, stage, and sub-
stage is presented in Table 1. Mixed breed dogs (27%)
and golden retrievers (12%) were the most common
breeds in this study.
Full staging was not performed for all dogs. Thirty-one
(94%) dogs had peripheral node involvement, while one
dog had thoracic and abdominal lymphadenopathy with
no peripheral lymphadenopathy, and one had a colonic
mass as the only site of disease. Eleven (33%) dogs were
thrombocytopenic and 7 (21%) were anemic prior to first
chemotherapy treatment. None of the dogs were hyper-
calcemic or azotemic. Sixteen (48%) dogs had thoracic
radiographs, 15 (45%) dogs had an abdominal ultra-
sound, and 2 (6%) had a bone marrow aspirate as part of
staging. Stage of disease, based on the World Health
Organization criteria for canine lymphoma, was not
evaluated for association with patient outcome due to
the low numbers of dogs with complete staging. Add-
itional sites of disease for the 31 dogs with peripheral
node involvement included circulating blasts on initial
complete blood cell count (CBC; n = 7), pulmonary par-
enchyma (n = 1), and nasal combined with dermal le-
sions (n = 1). Ten (30%) dogs were substage b and the
remaining 23 were considered substage a.
High-grade lymphoma was diagnosed with cytology in
28 dogs (85%) and histopathology in 5 dogs (15%). B-cell
phenotype was confirmed using CD79a for immunocyto-
chemistry (ICC) for 21 dogs (64%) and immunohisto-
chemistry (IHC) for 5 dogs (15%) [20]. Seven dogs (21%)
had lymph node aspirates submitted for flow cytometric
analysis to the Colorado State University Clinical Immun-
ology Laboratory (Fort Collins, CO); B-cell phenotype was
determined based on the presence of CD21 ± CD22 on an
expanded population of medium to large lymphocytes.
Treatment
Twenty-one (64%) dogs received L-ASP as induction
(400 kg/IU to a maximum of 10,000 units subcutane-
ously) prior to the first DOX treatment based on
Table 1 Baseline characteristics of patient population and
determination of B-cell immunophenotype (n = 33)
Parameter
Age (years) Mean ± SD 8.8 ± 2.9
Sex Male 2 (6%)
Neutered Male 13 (39%)
Female 1 (3%)
Spayed Female 17 (52%)
Weight (kg) Mean ± SD 27.6 ± 14.2
Breed Mixed breed 9 (27%)
Golden retriever 4 (12%)
German shepherd 2 (6%)
Scottish terrier 2 (6%)
Basset Hound 2 (6%)
Boxer 2 (6%)
Border collie 2 (6%)
Other (one each) 10 (31%)
Substage a 24 (73%)
b 9 (27%)
Immunophenotype ICC 21 (64%)
IHC 5 (15%)
Flow 7 (21%)
SD standard deviation, ICC immunocytochemistry, IHC immunohistochemistry
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clinician preference. The median interval between
L-ASP and DOX was 8 days (range, 4–21 days). All dogs
received prednisone at least equivalent to 1 mg/kg every
24 h; duration of use and schedule of prednisone taper-
ing was varied.
The median dosage of first doxorubicin was 30 mg/m2
(range, 17.5–30 mg/m2); 11 dogs weighed < 15 kg and
treatment initiated at 1 mg/kg. Seven dogs had DOX
therapy initiated at reduced dose, i.e. < 30 mg/m2 or <
1 mg/kg for dogs weighing less than 15 kg. The median
starting dose for these dogs was 27 mg/m2 (range, 25–
27 mg/m2). The median number of doxorubicin treat-
ments was 5 (range, 1–6 treatments); additional details
regarding the number of DOX treatments administered
is provided in Table 2. Eighteen (55%) dogs completed
the planned treatment protocol, whereas 15 (45%) dogs
did not complete their treatment protocol. Of the com-
pleted protocol group, 14 dogs completed a 5-treatment
protocol, while 4 dogs completed a 6-treatment protocol.
For those dogs that did not complete their planned
treatment protocol, progressive disease (PD) was deter-
mined during the course of treatment in 11 dogs as re-
corded in their medical record. In the remaining 4 dogs,
3 dogs died either from suspected PD or treatment re-
lated toxicities, and for 1 dog the owner elected to dis-
continue treatment and was lost to follow-up.
Outcome
Thirty-one dogs were able to be assessed for response to
treatment. One dog died the day following DOX admin-
istration and a second dog died of sepsis secondary to
neutropenia 9 days after DOX administration and
therefore response could not be assessed but was docu-
mented to be in a complete response (CR) at the time of
death. The overall response rate (ORR) for these 31 dogs
was 84% with 22 (71%) dogs experiencing a CR and 4
(13%) dogs experiencing a partial response (PR) as their
best response. There was no difference in response between
dogs that received a standard or reduced dose of DOX at
initiation (p = 1.0). Two dogs had stable disease (SD) and 3
dogs had PD as their best response. The median PFS for all
dogs was 147 days (range, 1–414 days; Fig. 1).
The OS for all dogs was 182 days (range, 1–556 days;
Fig. 1). Of the 28 dogs able to be offered rescue treat-
ment for progressive disease, 15 dogs received rescue
chemotherapy protocols other than prednisone alone.
Rescue agents included lomustine (8 dogs), mitoxan-
trone (6 dogs), COP (3 dogs), vincristine (3 dogs), vin-
cristine/cytarabine/melphalan (3 dogs), dacarbazine (2
dogs), L-ASP (2 dogs), and vincristine/cyclophospha-
mide/B-cell monoclonal antibody (Aratana Therapuetics,
Leawood, KS; 1 dog). Nine dogs continued with prednis-
one alone at the time of progression. Three dogs were lost
to follow-up at a median of 94 days (45–102 days after
treatment initiation) and censored at the date of last con-
tact. Two dogs were humanely euthanized due to sus-
pected DOX-induced gastrointestinal toxicity, 4 and
6 days post-infusion. The one-year survival rate for the 30
dogs with known outcomes was 23%, with 23 dogs con-
firmed dead within a year of treatment initiation. No dogs
were alive 2 years after the start of treatment.
Historical pre-treatment prognostic factors such as
substage, thrombocytopenia, and body weight were not
associated with PFS (Table 3). The only variable associ-
ated with improved PFS was protocol completion. The
only variables significant for OS were protocol comple-
tion and the addition of rescue chemotherapy beyond
Table 2 Doxorubicin and prednisone with or without L-
asparaginase treatment and patient response
Parameter
L-asparaginase at induction Yes 21 (64%)
No 12 (36%)
Number of doxorubicin treatments 1 7 (21%)
2 3 (9%)
3 3 (9%)
4 1 (3%)
5 15 (45%)
6 4 (12%)
Completed protocol Yes 18 (55%)
No 15 (45%)
Best response CR 22 (71%)
PR 4 (13%)
SD 2 (6%)
PD 3 (10%)
Not evaluated 2
Fig. 1 Kaplan-Meier curves of progression free survival (PFS) and
overall survival (OS) for 33 dogs treated with doxorubicin and
prednisone with or without L-asparaginase for B-cell lymphoma
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prednisone alone (Table 3). L-ASP induction was also
found not to have affected the PFS (p = 0.90), OS (p =
0.89), or ORR (p = 0.76) between the dogs who received
the induction or not. Dogs with substage b lymphoma
were not more likely to receive L-ASP than substage a
dogs (p = 0.26). There was also no difference in PFS or
OS for dogs that received 5 versus 6 doses of DOX (p =
0.82 and p = 0.87, respectively).
Discussion
This study sought to determine the response rate, PFS,
and OS for dogs with B-cell lymphoma when treated
with a DOX and prednisone protocol with or without
L-ASP induction; we hypothesized that dogs with B-cell
lymphoma would have an improved response rate and
outcome as compared to previous studies that included
dogs with T-cell forms of lymphoma. Our hypothesis
was not supported by our results as this DOX and pred-
nisone protocol, with or without L-ASP induction, re-
sulted in an ORR of 84%, PFS of 147 days, and OS of
182 days. While direct statistical comparison cannot be
made, these findings are numerically similar to previ-
ously reported DOX protocols when immunophenotype
was not assessed (ORR 74–88%; PFS 131–206 days; OS
169.5–295) [15–19]. Our study further supports that a
DOX and prednisone protocol continues to result in in-
ferior patient outcome as compared to the PFS and OS
previously reported for CHOP (PFS 140–282 days; OS
257–397 days) [1–5]. Completion of protocol was the
only variable that was associated with both improved
PFS and OS, which is a consequence of improved re-
sponse to treatment for a subset of patients. No previous
historical prognostic factors were found to be associated
with outcome, likely due to the evaluation of a more
homogenous group of dogs by excluding T-cell
immunophenotypes.
It is possible the variations in initially DOX or pred-
nisone dosing could have altered the response rate. We
feel this is unlikely, however, as the majority (79%) dogs
had treatment initiated at a standard DOX dose of
30 mg/m2 (or 1 mg/kg if less than 15 kg) and the me-
dian dose was only 10% reduced for those dogs that re-
ceived a reduced DOX dose at treatment initiation.
Additionally, there was no difference in response rates
between those two groups. Prednisone is administered
orally at home by owners and the tapering schedule was
not well documented in most medical records, so the
impact of this is challenging to assess. However, the role
that prednisone plays in the outcome of dogs with
lymphoma when they are treated with a multi-drug
chemotherapy protocol without the prednisone has been
called into question. There are now two prospective,
controlled studies that suggest that prednisone/prednis-
olone may not affect the response rate, PFS, or OS for
dogs with lymphoma [21, 22]. Based on this information,
the authors suspect that differences in prednisone dosing
and schedule likely have a negligible impact on patient
outcome.
An inherent limitation by the retrospective nature of
this study is the lack of standardization of response as-
sessment. The Veterinary Cooperative Oncology Group
(VCOG) consensus document, describing the evaluation
criteria for the treatment response of peripheral nodal
lymphoma in dogs is now the standard to measure
Table 3 Factors evaluated by univariate analysis for association with progression free survival (PFS) and overall survival (OS)
n Median PFS (days) p-value HR (95% CI) Median OS (days) p-value HR (95% CI)
Substage a 24 147 0.72 1.16 (0.491 to 2.92) 227 0.76 0.89 (0.379 to 2.00)
b 9 134 148
L-asparaginase at Induction No 12 147 0.9 0.95 (0.417 to 2.15) 245 0.89 0.95 (0.458 to 1.96)
Yes 21 147 152
Thrombocytopenia No 22 147 0.18 0.59 (0.210 to 1.30) 198 0.79 0.91 (0.416 to 1.95)
Yes 11 127 148
Body weight < 15 kg 8 147 0.57 0.76 (0.302 to 1.89) 138 0.63 1.219 (0.530 to 2.90)
> 15 kg 25 147 198
Anemia No 7 139 0.55 1.33 (0.540 to 3.35) 152 0.83 0.915 (0.382 to 2.17)
Yes 26 177 227
Protocol Completion No 18 61 < 0.0001 5.66 (17.3 to 324) 101 < 0.0001 4.59 (7.15 to 55.3)
Yes 15 170 291
Protocol Duration 5 tx 15 162 0.83 1.12 (0.384 to 3.38) 308 0.87 0.91 (0.289 to 2.83)
6 tx 4 185 226
Rescue Chemotherapy No 13 – – – 148 0.013 2.35 (1.36–7.30)
Yes 15 – 325
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disease response [23]. Lymph node measurements were
not recorded in the medical record for all patients at all
visits and therefore response to treatment was based on
clinician assessment as recorded in the medical record.
It is possible that based on the guidelines, some of the
partial responders may have been categorized as having
stable disease which could have led to an overestimation
of the ORR in this study. However, the VCOG guidelines
would not have altered the number of dogs that ob-
tained a CR, as determination of a CR is based on the
evaluator’s judgement that lymph nodes have returned
to normal size and are non-pathologic [23].
Similarly, toxicity of this protocol was not evaluated in
this study due to concern that retrospective assessment
of adverse events would be underestimated due to in-
complete information in the medical record. However,
four dogs were euthanized after their first dose of DOX.
One dog with substage b lymphoma died the day follow-
ing DOX administration, which could have been due to
advanced stage of disease or possibly acute tumor lysis
syndrome secondary to DOX administration. Two other
dogs were euthanized after developing gastrointestinal
toxicity 4 and 6 days after DOX treatment. However,
both of these dogs were also documented to have pro-
gressive disease at this time as well, so it is challenging
to elucidate retrospectively how lack of response to
treatment may have played a role in the decision to
euthanize when gastrointestinal signs secondary to DOX
developed. Gastrointestinal toxicity is a common sequala
of DOX administration, with up to 2/3 of dogs develop-
ing some degree of gastrointestinal toxicosis with < 15%
of those considered severe to life-threatening [17, 24,
25]. .A fourth dog was euthanized after becoming septic
after DOX-induced toxicity 9 days after treatment.
Hematologic toxicities are also commonly reported after
DOX administration and while most are mild in nature,
they can be severe enough to cause fatal complications
as others have reported as well [24, 26].
Higginbotham et al. described a single-agent DOX
protocol for the treatment of high-grade B-cell lymphoma,
which consisted of an initial induction of 3 treatments ad-
ministered every 2 weeks with additional DOX treatment
at the time of tumor progression [26]. Despite the differ-
ence in the timing of DOX administration, our continuous
protocol had a comparable median number of treatments
to the intermittent treatment protocol (5 treatments vs.
4.5 treatments), as well as similar outcomes (ORR of 78%
and median survival time of 169.5 days) [26]. Prospective
evaluation of continuous versus intermittent DOX admin-
istration could be considered to directly compare the effi-
cacy of these two protocols.
It is possible that the findings in this study were influ-
enced by tumor grade. A distinct biological behavior ex-
ists between histologic grades of canine lymphoma, with
low-grade lymphoma characterized by slow rate of pro-
gression, incomplete responses to DOX-based chemo-
therapy protocols, and longer survival times [7, 9, 27,
28]. While the distinction of high- and low-grade lymph-
oma is ideally made based on histopathological evalu-
ation, cytologic assessment of cell size is commonly used
in practice to make this determination and has been re-
ported to have a good correlation with histologic sam-
ples [29]. Previous studies of single-agent DOX
treatment of canine lymphoma have included both high-
and low-grade lymphomas when analyzing outcome.
Five (12%) dogs treated with single-agent DOX in two
previous studies were known to have low-grade lymph-
oma [15, 19]. The ORR and median survival times of
these studies were 76–88% and 237–270 days respect-
ively for all dogs treated. Although including low-grade
lymphomas may have negatively impacted the treatment
response rate, the median OS outcome was potentially
improved. All dogs in the present study had high-grade
lymphoma determined by either cytology or histopath-
ology. High-grade B-cell lymphoma, specifically diffuse
large B-cell lymphoma, in dogs has an aggressive bio-
logic behavior and when treated with a DOX-based
multi-agent chemotherapy protocol as described by
Childress et al. has an ORR of 100%, but a relatively
short PFI and OS of 252 and 341 days, respectively [10].
The inclusion of dogs with low-grade lymphoma in pre-
vious evaluations of single-agent DOX protocols may in
part explain why dogs with B-cell phenotype in this
study did not have an improved PFS or OS compared to
previous studies.
In addition to determining phenotype, flow cytometry
can provide cell size and level of antigen expression to
further sub-classify lymphomas. A subset of high-grade
B-cell lymphomas that have large cells and low MHC
class II expression are known to have median survival
times similar to high-grade T-cell lymphomas [30]. Only
21% of the dogs in this study were confirmed to have
B-cell origin lymphoma via flow cytometry, whereas al-
most 66% were confirmed by ICC. ICC can be beneficial
in conducting direct assessment of cell morphology in
combination with its immunoreactivity. However, poor
cytologic cellularity or quality can affect ICC interpret-
ation and quantification of antigen expression [31]. Cy-
tologic assessment of cell size is more subjective and
MHC class II expression is not routinely assessed with
ICC. Therefore, a subset of B-cell lymphomas with poor
prognostic factors may have been within this study
population, and potentially influencing the PFS and
OS negatively. In the future, as additional phenotypic
information becomes more readily available to
subcategorize high-grade B-cell lymphoma, this could
be used to further guide prognosis and treatment
recommendations.
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Many clinicians routinely initiate treatment for dogs
with substage b lymphoma with L-ASP at induction.
This practice allows time for owners to contemplate
their pets’ diagnosis and to decide on a treatment plan
which suits their goals in terms of providing quality of
life as well as logistics of finances and time. Dogs receiv-
ing L-ASP were included in this study since it has not
been found to result in increased remission or survival
duration when used at initiation of treatment [5, 32, 33].
Although the use of L-ASP at induction does not influ-
ence the outcome of dogs with lymphoma treated with a
CHOP protocol, two studies have reported that L-ASP
may be useful in the induction phase of treatment and
may or may not influence remission and survival times
with doxorubicin alone; however, results have been in-
consistent [5, 19, 34]. In our study, dogs that did not re-
ceive L-ASP had an improved OS when compared to the
population receiving L-ASP induction (245 vs. 152 days,
respectively); however, this result was not statistically
significant. The small sample size of this study precludes
robust statistical evaluation of the impact L-ASP has
when included at induction with DOX.
The limitations of this study are in part due to its
retrospective nature. Inherent with all retrospective
studies, some dogs were lost to follow-up and censored
from OS analysis (n = 3), and complete staging was not
performed in most dogs. Prednisone was administered
in addition to the DOX and could have led to an over
estimation of response rate. Many protocols incorporate
prednisone in the induction period to improve patients’
quality of life, and in this study the remission duration
and survival exceeded the known outcomes associated
with prednisone alone [9]. Inconsistent rescue therapy
and choice of euthanasia have an overall impact on OS,
especially if time and financial considerations are im-
portant factors. Lastly, the small sample size could have
impeded relevant statistical analysis.
Conclusions
A DOX and prednisone protocol, with or without L-ASP
induction, for the treatment of canine high-grade B-cell
lymphoma has similar response rates, PFS, and OS to pre-
viously published protocols that did not assess for immu-
nophenotype. While less efficacious than multi-agent
protocols for lymphoma, this protocol may be suitable for
owners unable to pursue a more time or financially inten-
sive protocol and who seek therapeutic benefit greater
than prednisone alone.
Methods
Study population
Dogs diagnosed with high-grade B-cell lymphoma and
treated with at least one dose of DOX were retrospectively
identified through the University of California, Davis
Veterinary Medical Teaching Hospital, Oregon State Uni-
versity Lois Bates Acheson Veterinary Teaching Hospital,
and Arizona Veterinary Oncology medical record data-
bases from January 2008 to December 2015. Inclusion cri-
teria comprised a diagnosis of high-grade lymphoma with
measurable disease present at treatment initiation, con-
firmed B-cell phenotype, and intent to treat with DOX
chemotherapy with no prior cytotoxic chemotherapy.
Signalment, body weight, age at diagnosis, clinical
signs at presentation, and pretreatment diagnostics, such
as CBC, serum chemistry panel, urinalysis, thoracic ra-
diographs, abdominal imaging, and bone marrow evalu-
ation, were abstracted from the medical record for each
dog. Lymph node cytology, histopathology, and/or re-
ports were reviewed to confirm reporting of large cell
morphology and to establish the method used for immu-
nophenotype determination.
Treatment
Dogs that had previously been treated with chemother-
apy were excluded; however, oral prednisone treatment
of ≤14 days and L-ASP induction ≤21 days prior to
DOX administration were acceptable. Each dog received
at least one dose of DOX administered intravenously
(30 mg/m2 for dogs > 15 kg or 1 mg/kg for dogs
≤15 kg). Subsequent DOX treatments were administered
every 3 weeks for five to six total treatments unless pro-
gressive disease occurred prior to completion of the pre-
scribed protocol.
Information obtained regarding the treatment protocol
included use of L-ASP induction, number of treatments,
and whether the DOX protocol was completed. Rescue
protocols were recorded in cases where relapse occurred,
and the owners elected additional therapy. Follow-up in-
formation was obtained from medical records and by
phone calls to the referring veterinary hospitals. Factors
evaluated for association with PFS and OS included sub-
stage, body weight, anemia, thrombocytopenia, hypercal-
cemia and/or azotemia at the time of diagnosis, number
of total treatments (5 versus 6), protocol completion,
and use of L-ASP at treatment induction. Patient out-
come criteria included maximal response to therapy,
PFS, and OS. A CR was considered as resolution of all
clinically detectable disease. A designation of PR, SD, or
PD was determined based on clinician assessment in the
medical record as lymph node measurements were not
recorded in all cases and standard VCOG criteria for
nodal lymphoma could not be retrospectively applied to
all cases. Responses and stable disease needed to be
maintained for a minimum of 21 days.
Statistical analyses
Continuous data were tested for normality using the
D’Agostino-Pearson test and reported using mean or
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median and range; categorical data were reported as fre-
quencies and percentages. ORR were defined as the
number of dogs experiencing partial or complete remis-
sion divided by the total number of dogs treated. Chi-s-
quare analysis was used to evaluate association between
use of L-ASP at induction and tumor response (CR, PR or
SD/PD). Fisher’s exact test was used to evaluate associ-
ation between substage and use of L-ASP at induction as
well as association between starting DOX dosage (stand-
ard versus reduced) and response (CR/PR versus SD/PD).
PFS was defined as the time of first treatment with either
L-ASP or DOX until progression of disease. OS was de-
fined as the time from first treatment with either L-ASP
or DOX and death from any cause. PFS and OS analyses
were performed using the Kaplan-Meier product limit
method. Dogs were censored at the date of last contact if
they were still alive at the time of analysis or last
follow-up. A p-value of ≤0.05 was considered statistically
significant. A commercially available software program
was used to perform statistical analyses (Prism v 6.0b,
GraphPad Software, La Jolla, CA).
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